title: Bisphosphonate-related osteonecrosis of the jaw.
abstract: Bisphosphonates are agents commonly used in the treatment of osteoporosis, and in the management of metastatic bone disease, and of hypercalcaemia of malignancy. Any oral surgical procedure or traumatic event exposing bone to bacterial infection may precipitate osteonecrosis of the jaw in subjects who have been treated with bisphosphonates which suppress bone turnover and inhibit the angiogenesis associated with healing. New guidelines for the treatment of bisphosphonate-related osteonecrosis of the jaw are emerging, but hitherto treatment has been empirically conservative.
authors.affiliation: Department of Periodontology and Oral Medicine, School of Oral Health Sciences, Faculty of Health Sciences, University of Limpopo, Medunsa Campus, South Africa. lfeller@ul.ac.za
authors.forename: L
authors.initials: L
authors.lastname: Feller
authors.forename: N H
authors.initials: NH
authors.lastname: Wood
authors.forename: R A G
authors.initials: RA
authors.lastname: Khammissa
authors.forename: U M E
authors.initials: UM
authors.lastname: Chikte
authors.forename: M
authors.initials: M
authors.lastname: Bouckaert
authors.forename: J
authors.initials: J
authors.lastname: Lemmer
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D016723:Bone Remodeling / Q000187:drug effects; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000628:therapy; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010020:Osteonecrosis / Q000139:chemically induced* / Q000628:therapy; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates